| human | Q5 |
| P496 | ORCID iD | 0000-0003-2612-9622 |
| P734 | family name | Arnold | Q694764 |
| Arnold | Q694764 | ||
| Arnold | Q694764 | ||
| P735 | given name | Eddy | Q15731557 |
| Eddy | Q15731557 | ||
| P106 | occupation | researcher | Q1650915 |
| P21 | sex or gender | male | Q6581097 |
| Q34779270 | 2'-deoxy-4'-C-ethynyl-2-halo-adenosines active against drug-resistant human immunodeficiency virus type 1 variants |
| Q27684365 | 3-Hydroxyquinolin-2(1 H )-ones As Inhibitors of Influenza A Endonuclease |
| Q27728086 | A New Class of Allosteric HIV-1 Integrase Inhibitors Identified by Crystallographic Fragment Screening of the Catalytic Core Domain |
| Q27675380 | A comparison of the ability of rilpivirine (TMC278) and selected analogues to inhibit clinically relevant HIV-1 reverse transcriptase mutants |
| Q35848043 | Advantages of crystallographic fragment screening: functional and mechanistic insights from a powerful platform for efficient drug discovery |
| Q35212611 | Alpha-carboxy nucleoside phosphonates as universal nucleoside triphosphate mimics |
| Q36290768 | Analysis of the Zidovudine Resistance Mutations T215Y, M41L, and L210W in HIV-1 Reverse Transcriptase |
| Q33529945 | Antigenic characteristics of rhinovirus chimeras designed in silico for enhanced presentation of HIV-1 gp41 epitopes [corrected]. |
| Q93083055 | Aryl and Arylalkyl Substituted 3-Hydroxypyridin-2(1H)-ones: Synthesis and Evaluation as Inhibitors of Influenza A Endonuclease |
| Q33417195 | Broad neutralization of human immunodeficiency virus type 1 (HIV-1) elicited from human rhinoviruses that display the HIV-1 gp41 ELDKWA epitope |
| Q34988326 | Chimeric rhinoviruses displaying MPER epitopes elicit anti-HIV neutralizing responses |
| Q27641581 | Crystal Structure of D-Hydantoinase from Burkholderia pickettii at a Resolution of 2.7 Angstroms: Insights into the Molecular Basis of Enzyme Thermostability |
| Q27667348 | Crystal Structure of tert -Butyldimethylsilyl-spiroaminooxathioledioxide-thymine (TSAO-T) in Complex with HIV-1 Reverse Transcriptase (RT) Redefines the Elastic Limits of the Non-nucleoside Inhibitor-Binding Pocket |
| Q27651402 | Crystal engineering of HIV-1 reverse transcriptase for structure-based drug design |
| Q30339085 | Crystal structure of RlmAI: implications for understanding the 23S rRNA G745/G748-methylation at the macrolide antibiotic-binding site. |
| Q27639371 | Crystal structure of a human rhinovirus that displays part of the HIV-1 V3 loop and induces neutralizing antibodies against HIV-1 |
| Q27642730 | Crystal structure of human tryptophanyl-tRNA synthetase catalytic fragment: insights into substrate recognition, tRNA binding, and angiogenesis activity |
| Q34575882 | Crystal structures of clinically relevant Lys103Asn/Tyr181Cys double mutant HIV-1 reverse transcriptase in complexes with ATP and non-nucleoside inhibitor HBY 097. |
| Q27679805 | Crystallographic Fragment Screening and Structure-Based Optimization Yields a New Class of Influenza Endonuclease Inhibitors |
| Q27657535 | Crystallographic Study of a Novel Subnanomolar Inhibitor Provides Insight on the Binding Interactions of Alkenyldiarylmethanes with Human Immunodeficiency Virus-1 Reverse Transcriptase |
| Q35967899 | Crystallography and the design of anti-AIDS drugs: conformational flexibility and positional adaptability are important in the design of non-nucleoside HIV-1 reverse transcriptase inhibitors |
| Q125902822 | Design of a SARS-CoV-2 papain-like protease inhibitor with antiviral efficacy in a mouse model |
| Q35796056 | Designing anti-AIDS drugs targeting the major mechanism of HIV-1 RT resistance to nucleoside analog drugs |
| Q27675974 | Detecting Allosteric Sites of HIV-1 Reverse Transcriptase by X-ray Crystallographic Fragment Screening |
| Q35654238 | Differential isotopic enrichment to facilitate characterization of asymmetric multimeric proteins using hydrogen/deuterium exchange mass spectrometry |
| Q92627280 | Discovery and Characterization of Fluorine-Substituted Diarylpyrimidine Derivatives as Novel HIV-1 NNRTIs with Highly Improved Resistance Profiles and Low Activity for the hERG Ion Channel |
| Q34303603 | Drug resistance in non-B subtype HIV-1: impact of HIV-1 reverse transcriptase inhibitors |
| Q33327065 | Exploring structural variability in X-ray crystallographic models using protein local optimization by torsion-angle sampling |
| Q27679282 | Extension into the entrance channel of HIV-1 reverse transcriptase—Crystallography and enhanced solubility |
| Q36455357 | Factors influencing the efficacy of rilpivirine in HIV-1 subtype C in low- and middle-income countries |
| Q26826945 | Fragment screening and HIV therapeutics |
| Q21128776 | GE23077 binds to the RNA polymerase 'i' and 'i+1' sites and prevents the binding of initiating nucleotides |
| Q27640888 | HIV-1 Reverse Transcriptase Structure with RNase H Inhibitor Dihydroxy Benzoyl Naphthyl Hydrazone Bound at a Novel Site |
| Q33900441 | HIV-1 reverse transcriptase and antiviral drug resistance. Part 1. |
| Q33900459 | HIV-1 reverse transcriptase and antiviral drug resistance. Part 2. |
| Q27676835 | HIV-1 reverse transcriptase complex with DNA and nevirapine reveals non-nucleoside inhibition mechanism |
| Q27649731 | High-resolution structures of HIV-1 reverse transcriptase/TMC278 complexes: strategic flexibility explains potency against resistance mutations |
| Q33945786 | Identification of alternative binding sites for inhibitors of HIV-1 ribonuclease H through comparative analysis of virtual enrichment studies |
| Q36072382 | In search of a novel anti-HIV drug: multidisciplinary coordination in the discovery of 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2- pyrimidinyl]amino]benzonitrile (R278474, rilpivirine). |
| Q24644413 | Inhibition of bacterial RNA polymerase by streptolydigin: stabilization of a straight-bridge-helix active-center conformation |
| Q30355077 | Molecular dynamics study of HIV-1 RT-DNA-nevirapine complexes explains NNRTI inhibition and resistance by connection mutations |
| Q34053804 | Molecular model of SARS coronavirus polymerase: implications for biochemical functions and drug design |
| Q33743954 | Mutations in HIV-1 reverse transcriptase affect the errors made in a single cycle of viral replication |
| Q30844876 | On the detection of multiple-binding modes of ligands to proteins, from biological, structural, and modeling data |
| Q27686740 | Phenyl substituted 3-hydroxypyridin-2(1H)-ones: inhibitors of influenza A endonuclease |
| Q30366846 | Phenyl substituted 4-hydroxypyridazin-3(2H)-ones and 5-hydroxypyrimidin-4(3H)-ones: inhibitors of influenza A endonuclease. |
| Q36970906 | Pronounced Inhibition Shift from HIV Reverse Transcriptase to Herpetic DNA Polymerases by Increasing the Flexibility of α-Carboxy Nucleoside Phosphonates |
| Q36438686 | Rapid experimental SAD phasing and hot-spot identification with halogenated fragments |
| Q27676461 | Snapshot of the equilibrium dynamics of a drug bound to HIV-1 reverse transcriptase |
| Q27657718 | Structural Basis for the Role of the K65R Mutation in HIV-1 Reverse Transcriptase Polymerization, Excision Antagonism, and Tenofovir Resistance |
| Q90654304 | Structural Basis of HIV-1 Inhibition by Nucleotide-Competing Reverse Transcriptase Inhibitor INDOPY-1 |
| Q34554996 | Structural Basis of Mycobacterium tuberculosis Transcription and Transcription Inhibition. |
| Q34494226 | Structural and molecular interactions of CCR5 inhibitors with CCR5. |
| Q27651800 | Structural basis for suppression of a host antiviral response by influenza A virus |
| Q28910458 | Structural basis for the unique biological function of small GTPase RHEB |
| Q27638026 | Structural basis of BLyS receptor recognition |
| Q24596976 | Structural basis of HIV-1 resistance to AZT by excision |
| Q24608460 | Structural basis of transcription initiation |
| Q33896402 | Structure and function of HIV-1 reverse transcriptase: molecular mechanisms of polymerization and inhibition |
| Q27658584 | Structure of HIV-1 Reverse Transcriptase with the Inhibitor β-Thujaplicinol Bound at the RNase H Active Site |
| Q27683831 | Structure of a Dihydroxycoumarin Active-Site Inhibitor in Complex with the RNase H Domain of HIV-1 Reverse Transcriptase and Structure–Activity Analysis of Inhibitor Analogs |
| Q24305273 | Structure of the guanylyltransferase domain of human mRNA capping enzyme |
| Q27684014 | Structures of HIV-1 RT-RNA/DNA ternary complexes with dATP and nevirapine reveal conformational flexibility of RNA/DNA: insights into requirements for RNase H cleavage |
| Q27640046 | Structures of HIV-1 reverse transcriptase with pre- and post-translocation AZTMP-terminated DNA. |
| Q24594359 | Structures of RNA polymerase-antibiotic complexes |
| Q28116883 | Structures of human cytosolic NADP-dependent isocitrate dehydrogenase reveal a novel self-regulatory mechanism of activity |
| Q30387969 | Structures of influenza A proteins and insights into antiviral drug targets. |
| Q27667836 | Synthesis, Activity, and Structural Analysis of Novel α-Hydroxytropolone Inhibitors of Human Immunodeficiency Virus Reverse Transcriptase-Associated Ribonuclease H |
| Q34674575 | Synthesis, biological activity, and crystal structure of potent nonnucleoside inhibitors of HIV-1 reverse transcriptase that retain activity against mutant forms of the enzyme |
| Q35975056 | Taking aim at a moving target: designing drugs to inhibit drug-resistant HIV-1 reverse transcriptases |
| Q24643039 | The RNA polymerase "switch region" is a target for inhibitors |
| Q27658127 | Three-dimensional EM structure of an intact activator-dependent transcription initiation complex |
| Q27683839 | Transcription inhibition by the depsipeptide antibiotic salinamide A |
| Q24652663 | Two-dimensional infrared spectra reveal relaxation of the nonnucleoside inhibitor TMC278 complexed with HIV-1 reverse transcriptase |
| Q25256872 | Why do HIV-1 and HIV-2 use different pathways to develop AZT resistance? |
Search more.